Patient treatment preferences in relapsed/refractory multiple myeloma

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 3 Dec 2018
Views: 1308
Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos

Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos meet in San Diego at the American Society of Hematology 2018 conference for an educational multiple myeloma panel discussion.

Their talk covers patient treatment preferences in relapsed/refractory multiple myeloma, and how this should impact treatment decisions made for this patient population.

Dr Mikhael chairs the discussion, opening the talk by outlining the potential treatment options available for relapsed/refractory multiple myeloma patients, and asking Prof Terpos to describe what ‘patient centred care’ looks like in his clinic.

He then directs the talk to Prof Chim, asking him, with all the different treatment options there are available for multiple myeloma patients, how he matches an individual patient to the therapy they should receive. Chim outlines a number of different factors that come into play when selecting a therapy for a patient and the conversations that should be had with the individual when making these decisions.

Dr Mikhael then summarises the key themes surrounding patient treatment preferences in relapsed/refractory multiple myeloma patients that have been seen from the data presented at ASH 2018; how the results reflect individual preferences, the changing trend in preference that is seen early in the disease course compared to later on, and the particular adverse events that patients look to avoid.

Prof Terpos then adds how the psychology and age of the patient can influence their preferred choice of treatment and discusses the convenience of different therapies for patients, with reference to how often they have to come in to clinic for treatments.

The discussion then moves to neuropathy in multiple myeloma patients and Prof Chim and Dr Mikhael discuss the significance of this adverse event in their patients and the preference surrounding this.
Dr Mikhael then directs the conversation to the evidence of the benefits of enhanced communication with Multiple Myeloma patients, and how this can impact their quality and quantity of life.

The discussion is finalised by summarising the key themes of the conversation and how communication with the patient can influence their long term outcomes.

What is patient centred care?
Tailoring treatment options for multiple myeloma patients
Key themes in disease management of multiple myeloma
Neuropathy in patients with multiple myeloma
The effect of communication on patient outcomes

This programme has been supported by an unrestricted educational grant from Takeda Pharmaceutical Company